Biotech executives and a handful of academics pleaded with U.S. and European regulators on Thursday to adopt new standards for approving antibody drugs against Covid, particularly for immunocompromised and other vulnerable patients.
The four-hour hearing came as agencies, companies, and researchers face a fundamental mismatch: The virus is evolving faster than our ability to develop interventions under normal — or even normal emergency — procedures.
The Food and Drug Administration pulled the last remaining antibody treatment, bebtelovimab, last month in the face of a swarm of new variants. Evusheld, the long-acting antibody used to protect cancer patients, transplant recipients, and others who don’t respond fully to vaccines, is still authorized but unlikely to provide much benefit.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
